AstraZeneca plc (AZN - Free Report) announced that Japan’sMinistry of Health, Labour and Welfare (MHLW) has granted approval to expand the label of Forxiga for the treatment of chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-II diabetes (T2D). The sNDA was based on positive results from the DAPA-HF phase III study on Farxiga.
Data from the DAPA-HF study showed that Forxiga, in addition to standard of care, reduced the risk of the composite outcome versus placebo by 26%.
Forxiga was approved in EU fora similar label expansion last month and in the United States in May 2020.
This year so far, AstraZeneca’s shares have risen 9.4% compared with an increase of 4.9% for the industry.
Several outcomes studies are ongoing on Farxiga for heart failure indications and chronic kidney disease (CKD) indications under the DapaCare clinical program. DAPA-HF is part of the DapaCare program. Farxiga (Forxiga’s name in United States) is being studied in the DELIVER study to evaluate its effect on patients with heart failure (HF) with preserved ejection fraction (HFpEF). DAPA-MI study is evaluating patients without T2D following an acute myocardial infarction (MI) or heart attack. DAPA-CKD has been conducted in patients with CKD.
Farxiga/Forxiga, a key top-line driver of AstraZeneca, generated sales worth $1.38 billion in the nine months of 2020, representing 26% growth at constant exchange rates. Farxiga enjoys global leadership with a significant market share.
Other SGLT2 inhibitors available in the market are Johnson & Johnson’s (JNJ - Free Report) Invokana and Lilly’s (LLY - Free Report) and Boehringer Ingelheim's Jardiance. Another successful diabetes medicine, which is not a SGLT2 drug, is Novo Nordisk’s (NVO - Free Report) GLP-1 drug, Victoza.
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
AstraZeneca plc (AZN - Free Report) announced that Japan’sMinistry of Health, Labour and Welfare (MHLW) has granted approval to expand the label of Forxiga for the treatment of chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-II diabetes (T2D). The sNDA was based on positive results from the DAPA-HF phase III study on Farxiga.
Data from the DAPA-HF study showed that Forxiga, in addition to standard of care, reduced the risk of the composite outcome versus placebo by 26%.
Forxiga was approved in EU fora similar label expansion last month and in the United States in May 2020.
This year so far, AstraZeneca’s shares have risen 9.4% compared with an increase of 4.9% for the industry.
Several outcomes studies are ongoing on Farxiga for heart failure indications and chronic kidney disease (CKD) indications under the DapaCare clinical program. DAPA-HF is part of the DapaCare program. Farxiga (Forxiga’s name in United States) is being studied in the DELIVER study to evaluate its effect on patients with heart failure (HF) with preserved ejection fraction (HFpEF). DAPA-MI study is evaluating patients without T2D following an acute myocardial infarction (MI) or heart attack. DAPA-CKD has been conducted in patients with CKD.
Farxiga/Forxiga, a key top-line driver of AstraZeneca, generated sales worth $1.38 billion in the nine months of 2020, representing 26% growth at constant exchange rates. Farxiga enjoys global leadership with a significant market share.
Other SGLT2 inhibitors available in the market are Johnson & Johnson’s (JNJ - Free Report) Invokana and Lilly’s (LLY - Free Report) and Boehringer Ingelheim's Jardiance. Another successful diabetes medicine, which is not a SGLT2 drug, is Novo Nordisk’s (NVO - Free Report) GLP-1 drug, Victoza.
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AZN - FREE
Get the latest research report on JNJ - FREE
Get the latest research report on NVO - FREE
Get the latest research report on LLY - FREE